메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

COREE Announces Discovery of Microbiome Biomarkers Spec…

[ 메디채널 김갑성 기자 ] Joint research achievement by Gemelli Hospital in Rome, COREE, COREE Pohang, and the Università Cattolica del Sacro Cuore SEOUL, South Korea, Sept. 26, 2025 -- COREE announced on September 15 that it had, for the first time in the world, identified microbiome biomarkers specific to diabetes and obesity patients, in collaboration with Italian research teams. The company is led by Chairman Chong-Yoon Lim, who is also the largest shareholder of Dx&Vx. The announcement was made at the 38th Annual Workshop of the European Helicobacter & Microbiota S
- 김갑성 기자
- 2025-09-26 21:00
Tescan acquires FemtoInnovations and launches Lase…

TAIPEI, Sept. 26, 2025 -- Tescan Group today announced the acquisition of FemtoInnovations, a leading innovator in ultrafast laser technologies, and the creation of a dedicated Laser Technology Business Unit (LT BU) headquartered at the University of Connecticut (UConn) Tech Park. The new unit expands Tescan's correlative and multimodal portfolio for semiconductor, biomedical device manufacturing, and advanced research markets. FemtoInnovations brings to TESCAN a unique and disruptive laser platform — technology already proven in demanding workflows and attracting strong inter
- 김갑성 기자
- 2025-09-26 14:47
CSL Vifor and Travere Therapeutics Recognize Updated KD…

FILSPARI® (sparsentan) suggested for IgA Nephropathy patients who are at risk of progressive kidney function loss ST. GALLEN, Switzerland, and SAN DIEGO, Sept. 26, 2025 -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) support the recent publication of the updated clinical practice guidelines for the treatment of IgA Nephropathy (IgAN), Kidney Disease: Improving Global Outcomes (KDIGO) 2025 clinical practice guideline for the management of IgA Nephropathy and Immunoglobulin A vasculitis. The updated guidelines define diagnostic criteria, treatment goals and treatm
- 김갑성 기자
- 2025-09-26 14:30
Titomic Appoints Aude Vignelles as President of Asia-Pacific…

MELBOURNE, Australia, Sept. 26, 2025 -- Titomic Limited (ASX: TTT), a global leader in Titomic Kinetic Fusion™, a cold spray additive manufacturing technology, is pleased to announce the appointment of Aude Vignelles as President of the Asia-Pacific Region (APAC), based in Melbourne. Ms. Vignelles brings an exceptional track record in aerospace, space, telecommunications, and advanced technology sectors, further strengthening Titomic's executive leadership during a pivotal period of regional growth and transformation. Aude Vignelles is the former Chief Technology Officer of the
- 김갑성 기자
- 2025-09-26 11:02
Tourism Malaysia and MHTC Bring Malaysia Fair 2025 to Suraba…

SURABAYA, Indonesia, Sept. 26, 2025 -- Tourism Malaysia, in collaboration with the Malaysia Healthcare Travel Council (MHTC), proudly presents Malaysia Fair 2025—a four-day celebration of Malaysia's culture, cuisine, tourism, and healthcare excellence. Taking place at Pakuwon Mall, Surabaya from 25 to 28 September 2025, the event marks the first-ever partnership between Tourism Malaysia and MHTC in support of Visit Malaysia 2026 (VM2026) and the Malaysia Year of Medical Tourism 2026 (MYMT2026) campaigns. Malaysia Fair 2025 positions Malaysia as both a premier leisure destinatio
- 김갑성 기자
- 2025-09-26 09:45
Catalent Announces Opening of its New Global Corporate He…

[ 메디채널 김갑성 기자 ] Relocation reflects a strategic expansion in Florida alongside long-standing manufacturing facility in nearby St. Petersburg New headquarters designed to support innovation, collaboration and growth TAMPA, Fla., Sept. 26, 2025 -- Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced the opening of its new global corporate headquarters in Tampa, Fla. The state-of-the-art site has been designed to showcase innovation, collaboration and excellence, supporting the Company's commitment to drivi
- 김갑성 기자
- 2025-09-26 09:00
Jacobio Chairman and Concerted Parties Increase Shareh…

BEIJING, SHANGHAI and BOSTON, Sept. 26, 2025 -- Jacobio Pharmaceuticals (1167.HK) today announced that its Chairman and Chief Executive Officer, Dr. Yinxiang Wang, together with concerted parties, have recently increased their shareholding in the Company by 11.06 million shares, representing a total investment of approximately HK$96.34 million. This action underscores their strong confidence in the Company's long-term growth prospects. In addition, the Company's share repurchase plan with an upper limit of HK$100 million, which was approved by the Board in July 2025, has already led to
- 김갑성 기자
- 2025-09-26 08:47
Building a National Lung Cancer Screening Model with AI: Ea…

BRISBANE, Australia and SEOUL, South Korea, Sept. 26, 2025 -- Coreline Soft announced today it will host an international webinar on Tuesday, October 14, sharing firsthand experiences and insights from the National Lung Cancer Screening Program (NLCSP) in Australia. The event, presented in collaboration with Lungscreen Australia, will explore the theme: "Building a National Model for Lung Cancer Screening in Australia." Australia officially launched its NLCSP on July 1, 2025. With three months of the program now underway, the upcoming webinar will serve
- 김갑성 기자
- 2025-09-26 07:00
어드밴시온, 2024년 기업 지속가능성 보고서 발간

4번째 연례 보고서에서는 지속 가능한 혁신, 안전, 책임감 있는 자원 관리의 꾸준한 진전 현황을 중점적으로 다룬다. 버팔로 그로브, 일리노이주, 2025년 9월 26일 -- 생명과학 분야용 완충용액과 독점 생산 특수 재료 분야의 세계 선두 기업인 어드밴시온(Advancion Corporation)(이하 '어드밴시온' 또는 '이 회사')이 오늘 2024년 기업 지속가능성 보고서를 발간한다고 발표했다. 보고서 전문은 advancionsciences.com/sustainability에서 확인할 수 있다. 어드밴시온은 포괄적인 지속가능성 보고서를 올해로 4년째 발간하고 있으며, 투명성, 책임감, 그리고 가시적인 영향력과 관련한 의지를 부단히 불태우고 있다. '과학을 원동력 삼아. 미래를 위한 설계(Driven by Science. Designed for the Future)'를 주제로 한 2024년 보고서에서는 어드밴시온이 혁신, 운영, 이해관계자 관계에 지속가능성을 접목하여 거시적으로 가치를 창출하는 방법을 주로 다루고 있다. 어드밴시온의 2024 보고서의 핵심 내용은 다음과 같다. 지속 가
- 김갑성 기자
- 2025-09-26 02:59
Bambusa Therapeutics Announces Highly Positive Healthy…

BOSTON, Sept. 25, 2025 -- Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation, today announced two landmark achievements for its lead program, BBT001. Last week, Bambusa Therapeutics unveiled highly positive results from the single ascending dose portion of its ongoing Phase I healthy volunteer study of BBT001 at the European Academy of Dermatology and Venereology (EADV) 2025. The data demonstrated: A favorable safety and tolerability profile a
- 김갑성 기자
- 2025-09-25 22:04

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2025-10-21_TUE

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 10월 21일 16시 20분